Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
13.62
+0.07 (0.52%)
At close: Jan 29, 2026, 4:00 PM EST
13.62
0.00 (0.00%)
After-hours: Jan 29, 2026, 4:10 PM EST
Pulse Biosciences Revenue
Pulse Biosciences had revenue of $86.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $86.00K.
Revenue (ttm)
$86.00K
Revenue Growth
n/a
P/S Ratio
10,807.35
Revenue / Employee
$1,147
Employees
75
Market Cap
922.99M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 700.00K | -718.00K | -50.63% |
| Dec 31, 2021 | 1.42M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DENTSPLY SIRONA | 3.62B |
| Embecta | 1.08B |
| Azenta | 593.82M |
| AtriCure | 518.31M |
| AngioDynamics | 307.31M |
| LeMaitre Vascular | 240.87M |
| STAAR Surgical Company | 230.59M |
| BioLife Solutions | 100.14M |
PLSE News
- 14 days ago - Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 20 days ago - Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors - Business Wire
- 23 days ago - Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium - Business Wire
- 4 weeks ago - Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation - Business Wire
- 7 weeks ago - Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology - Business Wire
- 3 months ago - Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences - Business Wire